SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Core Viewpoint - A securities class-action lawsuit has been initiated against Sarepta Therapeutics due to safety concerns and regulatory setbacks related to its gene therapy, ELEVIDYS, alleging that the company misled investors about the treatment's safety and efficacy [1]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta misrepresented ELEVIDYS as a safe and effective treatment with a clear path to regulatory approval [1]. - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, with a deadline for investors to serve as Lead Plaintiff set for August 25, 2025 [2]. - Hagens Berman is investigating claims on behalf of investors who suffered substantial losses and is encouraging those with knowledge of the situation to come forward [4]. Group 2: Regulatory Challenges - European regulators have rejected ELEVIDYS, with the European Medicines Agency (EMA) stating that a trial involving 125 children showed no significant improvement in movement for patients receiving the therapy compared to those receiving a placebo [3]. - The EMA's decision significantly impacts Sarepta's plans to expand in the European market and raises concerns about the effectiveness and safety of gene therapies [3]. Group 3: Timeline of Events - Key events leading to the lawsuit include a patient death in an ELEVIDYS trial reported on March 18, 2025, and a second patient death from acute liver failure on June 15, 2025, which led to the suspension of shipments for certain patient groups [6]. - The FDA issued a safety communication on June 24, 2025, confirming its investigation into the risk of acute liver failure associated with ELEVIDYS [6]. Group 4: Investigation and Whistleblower Information - Hagens Berman is actively seeking information from whistleblowers who may have non-public information regarding Sarepta, with potential rewards for original information provided to the SEC [5].